Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Burghaus, S; Drazic, P; Wolfler, M; Mechsner, S; Zeppernick, M; Meinhold-Heerlein, I; Mueller, MD; Rothmund, R; Vigano, P; Becker, CM; Zondervan, KT; Beckmann, MW; Fasching, PA; Berner-Gatz, S; Grunewald, FS; Hund, M; Kastner, P; Klammer, M; Laubender, RP; Wegmeyer, H; Wienhues-Thelen, UH; Renner, SP.
Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study
INT J GYNECOL OBSTET. 2023; Doi: 10.1002/ijgo.15062
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Wölfler Monika Martina
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: Objective To evaluate blood-based biomarkers to detect endometriosis and/or adenomyosis across nine European centers (June 2014-April 2018).Methods This prospective, non-interventional study assessed the diagnostic accuracy of 54 blood-based biomarker immunoassays in samples from 919 women (aged 18-45 years) with suspicion of endometriosis and/or adenomyosis versus symptomatic controls. Endometriosis was stratified by revised American Society for Reproductive Medicine stage. Symptomatic controls were "pathologic symptomatic controls" or "pathology-free symptomatic controls". The main outcome measure was receiver operating characteristic-area under the curve (ROC-AUC) and Wilcoxon P values corrected for multiple testing (q values).Results CA-125 performed best in "all endometriosis cases" versus "all symptomatic controls" (AUC 0.645, 95% confidence interval [CI] 0.600-0.690, q < 0.001) and increased (P < 0.001) with disease stage. In "all endometriosis cases" versus "pathology-free symptomatic controls", S100-A12 performed best (AUC 0.692, 95% CI 0.614-0.769, q = 0.001) followed by CA-125 (AUC 0.649, 95% CI 0.569-0.729, q = 0.021). In "adenomyosis only cases" versus "symptomatic controls" or "pathology-free symptomatic controls", respectively, the top-performing biomarkers were sFRP-4 (AUC 0.615, 95% CI 0.551-0.678, q = 0.045) and S100-A12 (AUC 0.701, 95% CI 0.611-0.792, q = 0.004).Conclusion This study concluded that no biomarkers tested could diagnose or rule out endometriosis/adenomyosis with high certainty.
Find related publications in this database (Keywords): adenomyosis; blood-based biomarkers; CA-125; diagnosis; endometriosis; S100-A12; sFRP-4